Immediate Impact
1 by Nobel laureates 64 standout
Citing Papers
The anti-PD-L1/CTLA-4 bispecific antibody KN046 plus lenvatinib in advanced unresectable or metastatic hepatocellular carcinoma: a phase II trial
2025 Standout
A covalent peptide-based lysosome-targeting protein degradation platform for cancer immunotherapy
2025 Standout
Works of Shuijing Yi being referenced
The tumor suppressor miR-138-5p targets PD-L1 in colorectal cancer
2016
Author Peers
| Author | Last Decade | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|
| Shuijing Yi | 48 | 33 | 236 | 232 | 70 | 19 | 380 | |
| Xuejie Zhu | 32 | 42 | 190 | 134 | 63 | 15 | 377 | |
| Wen Yuan | 25 | 35 | 226 | 151 | 46 | 28 | 350 | |
| Shilong Fu | 56 | 48 | 205 | 213 | 29 | 20 | 342 | |
| Bayley A. Jones | 55 | 38 | 220 | 104 | 34 | 23 | 368 | |
| Hongluan Mao | 77 | 91 | 230 | 160 | 37 | 22 | 443 | |
| Huiyu Zhuang | 57 | 144 | 232 | 129 | 51 | 21 | 428 | |
| Xiaoke Wu | 21 | 17 | 273 | 205 | 37 | 24 | 368 | |
| Victoria Cookson | 53 | 9 | 218 | 133 | 56 | 14 | 415 | |
| Xiujie Sheng | 55 | 42 | 286 | 224 | 18 | 23 | 439 | |
| Meilian Dong | 34 | 39 | 118 | 130 | 51 | 16 | 360 |
All Works
Login with ORCID to disown or claim papers
Loading papers...